KDM1A and essential thrombocythemia: Bomedemstat, an irreversible LSD1 inhibitor, reduced platelet counts to ≤400 × 109/liter in the absence of new thromboembolic events in 95% of patients (61 of 64) with essential thrombocythemia (213).